Sod Phenylbutyrat/Taurursodiol
Brand name: Relyvrio
Rank #189 of 500 drugs by total cost
$77.0M
Total Cost
6,152
Total Claims
$77.0M
Total Cost
142
Prescribers
$13K
Cost per Claim
804
Beneficiaries
6,228
30-Day Fills
$542K
Avg Cost/Provider
43
Avg Claims/Provider
About Sod Phenylbutyrat/Taurursodiol
Sod Phenylbutyrat/Taurursodiol (sold as Relyvrio) was prescribed 6,152 times by 142 Medicare Part D providers in 2023, costing the program $77.0M. At $13K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 186 | Montelukast Sodium (Montelukast Sodium) | $81.3M | 5,086,706 |
| 187 | Certolizumab Pegol (Cimzia) | $79.9M | 11,784 |
| 188 | Celecoxib (Celecoxib) | $77.7M | 1,938,505 |
| 189 | Sod Phenylbutyrat/Taurursodiol (Relyvrio) | $77.0M | 6,152 |
| 190 | Pravastatin Sodium (Pravastatin Sodium) | $76.8M | 4,033,829 |
| 191 | Lanadelumab-Flyo (Takhzyro) | $76.5M | 1,670 |
| 192 | Diltiazem Hcl (Diltiazem 24hr Er (Cd)) | $75.9M | 1,846,124 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology